|

Lupus Clinical Trials in Boston, MA

18 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 3<1 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/3<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 2<1 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 2<1 mi
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseasePhase 1<1 mi
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Phase 2<1 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPhase 1/2<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesPhase 1<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Phase 25 mi
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry—9 mi
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives—9 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/239 mi
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPhase 339 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—39 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.